Cytokinetics (NASDAQ:CYTK – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC ...

Stifel initiated coverage on Cytokinetics Incorporated (NASDAQ:CYTK), noting the company’s catalyst rich one to two years.

Dutch Prime Minister Dick Schoof anticipates President Donald Trump to continue urging the country to restrict ASML's exports ...

Fintel reports that on January 22, 2025, Stifel initiated coverage of Cytokinetics (NasdaqGS:CYTK) with a Buy recommendation.

Stifel has initiated coverage of Cytokinetics (NASDAQ:CYTK) with a buy rating, citing its drug aficamten. The bank noted the stock was "out of favor" in the wake of a "controversial" deal with Royalty ...

JPMorgan initiates coverage of SNCY with Overweight rating and $23 target. Charter and Cargo ops contribute 33% of revenues, ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors ...